Israel Englander Viking Therapeutics, Inc. Transaction History

Millennium Management LLC

$207 Billion
Q2 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 11,600 shares of VKTX stock, worth $714,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,600

Previous 10,200 13.73%

Holding current value

$714,908

Previous $836,000 26.56%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$47.39 - $80.2 $15.4 Million - $26.1 Million	325,925 Added 82.08%	723,014 $38.3 Million
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $100,345 - $544,981	-5,767 Reduced 1.43%	397,089 $32.6 Million
Q4 2023 Feb 14, 2024	SELL	$9.24 - $19.64 $13.1 Million - $27.9 Million	-1,420,264 Reduced 77.9%	402,856 $7.5 Million
Q2 2023 Aug 14, 2023	SELL	$14.84 - $24.79 $29.9 Million - $49.9 Million	-2,014,876 Reduced 52.5%	1,823,120 $29.6 Million
Q1 2023 May 15, 2023	SELL	$8.08 - $17.33 $4.4 Million - $9.44 Million	-544,504 Reduced 12.42%	3,837,996 $63.9 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $3.48 Million - $12 Million	1,279,469 Added 41.23%	4,382,500 $41.2 Million
Q3 2022 Nov 14, 2022	BUY	$2.55 - $3.89 $4.56 Million - $6.96 Million	1,788,275 Added 136.02%	3,103,031 $8.44 Million
Q2 2022 Aug 15, 2022	SELL	$2.11 - $3.15 $394,844 - $589,459	-187,130 Reduced 12.46%	1,314,756 $3.8 Million
Q1 2022 May 16, 2022	BUY	$3.0 - $4.88 $3.89 Million - $6.33 Million	1,296,236 Added 630.31%	1,501,886 $4.51 Million
Q4 2021 Feb 14, 2022	BUY	$4.6 - $6.72 $673,633 - $984,090	146,442 Added 247.33%	205,650 $946,000
Q3 2021 Nov 15, 2021	BUY	$5.58 - $7.04 $64,348 - $81,185	11,532 Added 24.19%	59,208 $372,000
Q2 2021 Aug 16, 2021	BUY	$5.19 - $6.73 $247,438 - $320,859	47,676 New	47,676 $286,000
Q4 2020 Feb 16, 2021	SELL	$5.3 - $6.71 $185,982 - $235,460	-35,091 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$5.73 - $8.11 $2.09 Million - $2.97 Million	-365,603 Reduced 91.24%	35,091 $204,000
Q2 2020 Aug 14, 2020	BUY	$4.35 - $8.08 $1.54 Million - $2.86 Million	353,447 Added 748.08%	400,694 $2.89 Million
Q1 2020 May 14, 2020	BUY	$3.45 - $7.95 $163,002 - $375,613	47,247 New	47,247 $221,000
Q4 2019 Feb 14, 2020	SELL	$6.38 - $8.73 $1.08 Million - $1.48 Million	-169,070 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$6.55 - $8.6 $1.11 Million - $1.45 Million	169,070 New	169,070 $1.16 Million
Q1 2019 May 14, 2019	SELL	$7.58 - $9.94 $628,382 - $824,026	-82,900 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$7.16 - $16.21 $2.05 Million - $4.64 Million	-286,516 Reduced 77.56%	82,900 $634,000
Q3 2018 Nov 14, 2018	SELL	$9.7 - $19.65 $3.6 Million - $7.29 Million	-371,188 Reduced 50.12%	369,416 $6.44 Million
Q2 2018 Aug 14, 2018	SELL	$3.88 - $12.74 $2.56 Million - $8.39 Million	-658,766 Reduced 47.08%	740,604 $7.03 Million
Q1 2018 May 15, 2018	BUY	$4.11 - $6.93 $2.86 Million - $4.83 Million	696,398 Added 99.06%	1,399,370 $6.12 Million
Q4 2017 Feb 14, 2018	BUY	$1.74 - $4.34 $1.22 Million - $3.05 Million	702,972	702,972 $2.85 Million

Others Institutions Holding VKTX

# of Institutions

442

Shares Held

63.3M

Call Options Held

6.23M

Put Options Held

2.97M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.73B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account